Copenhagen-based VentriJect, a MedTech startup, recently raised €1.7 million in a funding round. Existing investors primarily led this investment, joined by the Export and Investment Fund of Denmark (EIFO), TechStation | HardTech Innovation Hub, Investo Capital, and private investor Carsten Stendevad. This VentriJect raise supports the company's expansion of its cardiorespiratory fitness monitoring device.
Expanding Cardiorespiratory Fitness Monitoring
VentriJect's flagship device, Seisomofit, is a CE-marked medical device. It utilizes seismocardiography to measure chest wall movements from heart vibrations. Consequently, the system estimates a person's VO2 max in under three minutes without exercise. Furthermore, the VentriJect algorithm then delivers this depiction via an app.
Founded in 2018 as an Aalborg University spinout, VentriJect commercialized its product by 2021. Its technology has both medical and fitness applications.
VentriJect currently serves customers across several European markets. The company recently signed distributors in Denmark, the Netherlands, Sweden, Switzerland, and the UK. Furthermore, it is negotiating with various healthcare providers across Europe. VentriJect also explores US market entry, aiming for access to over 55,000 health clubs. This expansion aligns with a broader interest in healthtech within the Nordic startups scene, attracting significant investment. Unlike general fitness trackers such as Garmin or Fitbit, VentriJect's medical-grade device offers precise measurements.
